Doxycycline for the prevention of progression of covid-19 to severe disease requiring intensive care unit (icu) admission: a randomized, controlled, open-label, parallel group trial (doxprevent.icu)

HIGHLIGHTS

SUMMARY

Despite these advances, there remains a high unmet need for treatments that prevent COVID-19 progression in hospitalized patients to severe disease requiring transfer to an intensive care unit (ICU). Doxycycline may be an effective treatment in hospitalized patients, who are at high risk for progressing to severe COVID-19 that requires treatment in ICU. The need for ICU admission was chosen as Doxycycline for treatment of severe COVID-19 the primary outcome, and the study was powered based on the assumption that, with standard of care treatments (SoC) at the time of protocol . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.